Relationship between plasma phospholipid transfer protein activity and HDL subclasses among patients with low HDL and cardiovascular disease

Atherosclerosis

Volumn 142, Issue 1, 1999, Pages 201-205

  C Cheung, Marian ^a   Wolfbauer, Gertrud ^a   Greg Brown, B ^a   J Albers, John ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cardiovascular disease; High density lipoproteins; Phospholipid transfer protein

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROTEIN ANALYSIS;

APOLIPOPROTEINS A; CARRIER PROTEINS; CORONARY DISEASE; FEMALE; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS; LIPOPROTEINS, HDL; MALE; MEMBRANE PROTEINS; PARTICLE SIZE; PHOSPHOLIPID TRANSFER PROTEINS; PHOSPHOLIPIDS; RISK FACTORS;

EID: 0032890468     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00190-7     Document Type: Article

References (31)

1. Gordon D.J., Rifkind B.M. High-density lipoprotein - the clinical implications of recent studies. New. Engl. J. Med. 321:1989;1311-1316.
2. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs D.R. J.r, Bangdiwala S., Tyroler H.A. High density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 79:1989;8-15.
3. Cheung M.C., Brown B.G., Wolf A.C., Albers J.J. Altered particle size distribution of apolipoprotein A-1 containing lipoproteins in subjects with coronary artery disease. J. Lipid. Res. 32:1991;383-394.
4. Kottke B.A., Zinsmeister A.R., Holmes D.R. J.r, Kneller R.W., Hallaway B.J., Mao S.J. Apolipoproteins and coronary artery disease. Mayo. Clin. Proc. 61:1986;313-320.
5. Rubin E.M., Krauss R.M., Spangler E.A., Verstuyft J.G., Clift S.M. Inhibition of early atherogenesis in transgenic mice by apolipoprotein A-I. Nature. 353:1991;265-267.
6. Warden C.H., Hedrick C.C., Qiao J.-H., Castellani L.W., Lusis A.J. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 261:1993;469-472.
7. Schultz J.R., Verstuyft J.G., Gong E.L., Nichols A.V., Rubin E.M. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 365:1993;762-764.
8. Maher V.M.G., Brown B.G., Zhao X.-Q., Cheung M., Marcovina S.M., Albers J.J. Contrasting effects of apoprotein A-I and A-II on coronary artery disease change in men during 2.5 years of lipid-lowering therapy. J. Am. Coll. Cardiol. 23:1994;100A.
9. 125I-labeled lipoproteins with specific polypeptide antisera. Evidence for two populations with differing polypeptide composition in human high density lipoprotein. Biochemistry. 10:1971;3436-3442.
10. Cheung M.C., Albers J.J. Characterization of lipoprotein particles isolated by immunoaffinity chromatography: particles containing A-I and A-II and particles containing A-I but no A-II. J. Biol. Chem. 259:1984;12201-12209.
11. Rader D.J., Castro G., Zech L.A., Fruchart J.-C., Brewer H.B. J.r. In vivo metabolism of apolipoproteins A-I on high density lipoprotein particles LpA-I and LpA-I, A-II. J. Lipid. Res. 32:1991;1849-1859.
12. Tilly-Kiesi M., Lichtenstein A.H., Joven J., Vilella E., Cheung M.C., Carrasco W.V., Ordovas J.M., Dolnikowski G., Schaefer E.J. Impact of gender on the metabolism of apolipoprotein A-I in HDL subclasses LpAI and LpAI:AII in older subjects. Arteroscler. Thromb. Vasc. Biol. 17:1997;3513-3518.
13. Fruchart J.C., De Geteire C., Delfly B., Castro G.R. Apolipoprotein A-I-containing particles and reverse cholesterol transport: evidence for connection between cholesterol efflux and atherosclerosis risk. Atherosclerosis. 110:1994;S35-S39.
14. Fielding C.J., Fielding P.E. Molecular physiology of reverse cholesterol transport. J. Lipid. Res. 36:1995;211-228.
15. Tu A.-Y., Nishida H.I., Nishida T. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J. Biol. Chem. 268:1993;23098-23105.
16. 1-HDL. Biochim. Biophys. Acta. 1301:1996;255-262.
17. Jiang X.-C., Francone O.L., Bruce C., Milne R., Mar J., Walsh A., Breslow J.L., Tall A.R. Increased preß-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J. Clin. Investig. 96:1996;2373-2380.
18. Tall A.R., Krumholz S., Olivercrona T., Deckelbaum R.T. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J. Lipid. Res. 26:1985;842-851.
19. Tollefson J.H., Ravnik S., Albers J.J. Isolation and characterization of a phospholipid transfer protein (LTP-II) from human plasma. J. Lipid. Res. 29:1988;1593-1602.
20. Albers J.J., Tu A.-Y., Paigen B., Chen H., Cheung M.C., Marcovina S.M. Transgenic mice expressing human phospholipid transfer protein have increased HDL/non-HDL cholesterol ratio. Int. J. Clin. Lab. Res. 26:1996;262-267.
21. Föger B., Santamarina-Fojo S., Shamburek R.D., Parrot C.L., Talley G.D., Brewer H.B. J.r. Plasma phospholipid transfer protein: adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL. J. Biol. Chem. 272:1997;27393-27400.
22. Warnick G.R. Enzymatic methods for quantification of lipoprotein lipids. Methods. Enzymol. 129:1986;101-123.
23. 2+ precipitation procedure for quantitation of high density lipoprotein cholesterol. Clin. Chem. 28:1982;1379-1388.
24. Bachorik P.S., Albers J.J. Precipitation methods for quantification of lipoproteins. Methods. Enzymol. 128:1986;78-100.
25. Cheung M.C., Wolf A.C. In vitro transformation of apoA-I-containing lipoprotein subpopulations: role of lecithin:cholesterol acyltransferase and apoB-containing lipoproteins. J. Lipid. Res. 30:1989;499-509.
26. Cheung M.C., Wolfbauer G., Albers J.J. Plasma phospholipid mass transfer rate: relationship to plasma phospholipid and cholesteryl ester transfer activities and lipid parameters. Biochim. Biophys. Acta. 1303:1996;103-110.
27. Cheung M.C., Austin M.A., Moulin P., Wolf A.C., Cryer D., Knopp R.H. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis. 102:1993;107-119.
28. Jauhiainen M., Metso J., Pahlman R., Blomqvist S., van Tol A., Ehnholm C. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J. Biol. Chem. 268:1993;4032-4036.
29. Lusa S., Jauhiainen M., Metso J., Somerharju P., Ehnholm C. The mechanism of human plasma phospholipid transfer protein-induced enlargement of high density lipoprotein particles: evidence for particle fusion. Biochem. J. 313:1996;275-282.
30. Albers J.J., Wolfbauer G., Cheung M.C., Day J.R., Ching A.F.T., Lok S., Tu A.-Y. Functional expression of human and mouse phospholipid transfer protein: Effect of recombinant and plasma PLTP on HDL subspecies. Biochim. Biophys. Acta. 1258:1995;27-34.
31. Syvanne M., Castro G., Dengremont C., De Geitere C., Jauhiainen M., Ehnholm C., Michelagnoli S., Franceschini G., Kahri J., Taskinen M.-R. Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. Atherosclerosis. 127:1996;245-253.